Elle Investments
Contributor since: 2018
Company: Elle investments
Articles
scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Fennec Pharmaceuticals: The PEDMARK NDA Has Been Accepted, We Remain Bullish On The November PDUFA Catalyst
scPharmaceuticals Inc.: The FUROSCIX CRLs Have Created An Excellent Buying Opportunity
Townsquare Media: Slowly Returning To Normal, Our Thesis Is Playing Out
Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results
ACCO Brands Corporation: We Like The Chances Of A Quick 40-80% Return
Liquidia Technologies: The Odds Of Approval Are Unclear, But The Potential Upside Makes It A Good Bet
Actinium Pharmaceuticals: Far Enough Along For A Small Bet
Akebia Therapeutics: The Drop From The Missed Safety Endpoint Offers A Good Reentry Point
Civeo Corporation: Positive Cash Flow For 2020 And Beyond Makes This Worth The Risk
Iridex Corporation: Deserves More Patience Given Shift In Commercial Strategy And Aggressive Cost Cutting
Verrica Pharmaceuticals: The Fundamentals Aren't So Clear, But The Stock Chart May Be Telling Us Something
ZAGG: Another Mispricing Exacerbated By The Pandemic
Vera Bradley: An Attractive Contrarian Bet In Retail
Bausch Health: Investors Were Acknowledging The Turnaround Before COVID-19 Struck
Townsquare Media: The Lack Of Participation In The Recent Market Rally Is A Buying Opportunity
AcelRx Pharmaceuticals: Finally Light At The End Of The Tunnel
ObsEva Has A Promising Candidate For An Unmet Need - Behind The Idea
ObsEva Has A Promising Candidate For An Unmet Need
Advanced Micro Devices: A Solid Buy
Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off - Behind The Idea
Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off
Xinyuan Real Estate Co.: Q4 2019 Recap
Omeros Corporation: The Thesis Was Playing Out Before COVID-19 Hit
American Superconductor Corporation: A Great Short-Term And Long-Term Opportunity - Behind The Idea
American Superconductor Corporation: A Great Short-Term And Long-Term Opportunity
Fennec Pharmaceuticals: Market Fatigue Due To A Lack Of Catalysts Has Created A Mispricing
Fennec Pharmaceuticals: Market Fatigue Due To A Lack Of Catalysts Has Created A Mispricing - Behind The Idea
AstroNova: Even With The Recent Decline, It's Not A Clear Buying Opportunity
Spectrum Pharmaceuticals: Stock Price Drop Vs. Disappointing Clinical Data Provides Good Upside
Galectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows
Akebia Therapeutics: No Change To The Thesis, And The Lower Entry Point Improves The Bet
Xinyuan Real Estate Co.: The 10% Dividend Yield Makes For An Even Better Entry Point
BeyondSpring: The Drop From The Capital Raise Offers A Good Entry Point
VOXX International Corporation: The Net Assets Per Share Limit The Downside
Spectrum Pharmaceuticals: Great Asset, Great Liquidity, Low Price
Behind The Idea: Spectrum Pharma - Great Asset
Omeros: The Commercial Prospects Remain Bright
Akebia Therapeutics: Still A Strong Buy After The 50% Decline
Tailored Brands: Down A Lot Recently, But Holding Steady After 1QFY19 Earnings